PBS, 5% trehalose
Store as concentrated solution. Centrifuge briefly prior to opening vial. For short-term storage (1-2 weeks), store at 4ºC. For long-term storage, aliquot and store at -20ºC or below. Avoid multiple freeze-thaw cycles.
recombinant human ALK-1 extracellular domain expressed in mouse NSO cells.
Purified by affinity chromatography
For laboratory use only. Not for any clinical, therapeutic, or diagnostic use in humans or animals. Not for animal or human consumption.
Activin A Receptor Like Type 1,Acvrlk1,Alk-1,Alk1,Hht,Hht2,Orw2,Skr3,Tsr-I,Acvrl1
The TGF-beta superfamily of ligands exerts its biological activity by binding to heteromeric receptor complexes two types (I and II) of the serine/threonine kinases. Type II receptors are constitutively active kinases, which phosphorylate type I receptors after ligand binding. In turn, the activated type I kinases phosphorylate downstream signaling molecules including the various smads. Seven type I receptors, also termed activin receptor-like kinase (ALK), have been isolated from mammals. The physiological ligand for ALK1 is currently unknown. It is suggested that TGF-beta 1 and TGF-beta 3 can activate chimeric ALK1. ALK1, like the other type I receptors, contains a cysteine rich domain with conserved cysteine spacing in the extracellular region and a glycine and serine rich domain preceding the kinase domain. The reduced human ALK1 monomer has a calculated molecular mass of approximately 37.3 kDa. Due to glycoslyation, the recombinant human protein migrates as a 50-55 kDa protein in SDS-PAGE under reducing conditions. Human and mouse ALK1 share approximately 71% amino acid sequence identity in their extracellular domains. ALK1 is highly expressed in endothelial cells and other vascular tissues. Mutations in ALK1 are associated with hereditary hemorrhagic telangiectasia (HHT), suggesting an important role for ALK1 in the control of blood vessel development and repair.